Search results for "Cancer Pain"

showing 10 items of 134 documents

Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.

2008

The aim of this study was to compare the analgesic and adverse effects, doses, as well as cost of opioid drugs, supportive drug therapy and other analgesic drugs in patients treated with oral sustained-release morphine, transdermal fentanyl, and oral methadone.One hundred and eight cancer patients, no longer responsive to opioids for moderate pain, were selected to randomly receive initial daily doses of 60 mg of oral sustained-release morphine, 15 mg of oral methadone, or 0.6 mg (25 microg/h) of transdermal fentanyl. Oral morphine was used as breakthrough pain medication during opioid titration. Opioid doses, pain intensity, adverse effects, symptomatic drugs, were recorded at week interva…

MaleCost-Benefit AnalysisAdministration OralFentanylNeoplasmscancer pain opioidsProspective StudiesCancer painTransdermalIntractableAnalgesicsMorphineMiddle AgedPain IntractableAnalgesics OpioidFentanylNeuropsychology and Physiological PsychologyTreatment OutcomeNeurologyPatient SatisfactionAnesthesiaAdministrationFemaleDrugmedicine.drugOralAdultAdolescentAnalgesicPainOpioidAdministration CutaneousDrug Administration ScheduleDose-Response RelationshipmedicineHumansAdverse effectAgedDose-Response Relationship Drugbusiness.industryCostsCutaneousAnesthesiology and Pain MedicineOpioidCancer pain; Costs; Fentanyl; Methadone; Morphine; Administration Cutaneous; Administration Oral; Adolescent; Adult; Aged; Analgesia; Analgesics Opioid; Cost-Benefit Analysis; Dose-Response Relationship Drug; Drug Administration Schedule; Female; Fentanyl; Humans; Male; Methadone; Middle Aged; Morphine; Neoplasms; Pain Intractable; Patient Satisfaction; Prospective Studies; Quality of Life; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology; Neuropsychology and Physiological PsychologyMorphineQuality of LifeAnalgesiaCancer painbusinessMethadoneMethadoneEuropean journal of pain (London, England)
researchProduct

Hyperalgesia: An Emerging Iatrogenic Syndrome

2003

Clinical reports suggest that opioids, intended to abolish pain, can unexpectedly produce hyperalgesia. This paradoxical effect may be mechanistically related to tolerance induced by increasing doses of opioids. Two case reports illustrate a syndrome characterized by increasing pain pursued by escalating opioid doses, which results in a worsening of the clinical picture. Several experimental data may help explain the course of this challenging clinical condition. In escalating opioid doses rapidly, a risk of opioid-induced hyperalgesia should be recognized, as higher doses of opioids may stimulate rather than inhibit the central nervous system by different mechanisms. Alternative procedures…

MaleDiagnostic informationbusiness.industryIatrogenic DiseaseCentral nervous systemPainMiddle AgedBioinformaticsAnalgesics OpioidAnesthesiology and Pain Medicinemedicine.anatomical_structureOpioidHyperalgesiaNeoplasmsAnesthesiaHyperalgesiaIatrogenic diseaseHumansMedicineNeurology (clinical)medicine.symptombusinessCancer painGeneral Nursingmedicine.drugJournal of Pain and Symptom Management
researchProduct

Cancer pain undertreatment and prognostic factors

2012

MaleOncologymedicine.medical_specialtybusiness.industryMEDLINEPainAnesthesiology and Pain MedicineText miningNeurologyNeoplasmsInternal medicineHumansMedicineFemaleNeurology (clinical)businessCancer painPain
researchProduct

Methadone response in advanced cancer patients with pain followed at home

1999

Concerns about the safety of therapy with methadone, which may arise because of its pharmacokinetic characteristics and inappropriate dosing, may deter clinicians from using this drug, especially in elderly patients. Experience is accumulating that the drug may be used safely and successfully if low doses are given initially and care is taken in the titration of the dose against the pain. A prospective study was carried out in a consecutive sample of 45 advanced cancer patients followed at home, who had never received other strong opioids for their pain. Patients were treated with an oral liquid preparation of methadone, which was administered 2-3 times daily, according to need. Doses were …

MaleOpioidAdverse effectSex FactorsNeoplasmsHumansMedicineProspective StudiesDosingCancer painAdverse effectProspective cohort studyGeneral NursingNursing (all)2901 Nursing (miscellaneous)Pain Measurementbusiness.industryMiddle AgedHome Care ServicesMiddle agePain IntractableAnalgesics OpioidAnesthesiology and Pain MedicineAnesthesiaNeuropathic painAmbulatoryFemaleNeurology (clinical)businessCancer painMethadoneMethadonemedicine.drug
researchProduct

Investigation of an opioid response categorization in advanced cancer patients

1999

The aim of this study was to investigate a possible distinction in three categories of opioid response and to identify possible factors associated with a poor response. A prospective survey was carried out in 105 consecutive patients requiring morphine for at least 4 weeks before death. Mean pain intensity, opioid doses and symptom intensity at weekly intervals, pain syndromes, and the presence of psychological distress were assessed. Opioid escalation index (OEI%) was calculated from the parameters recorded. Three categories were considered, including (1) patients with slow increments of opioid dose and a mean analgesic 10-cm visual analogue scale (VAS) less than 4 (responders), (2) patien…

MaleOpioid-responsivenePalliative careNauseaVisual analogue scaleAnalgesicPainNeuropathic painNeoplasmsmedicineHumansProspective StudiesCancer painProspective cohort studyGeneral NursingNursing (all)2901 Nursing (miscellaneous)AgedDose-Response Relationship DrugMorphinebusiness.industryData CollectionPsychological distrePalliative CareMiddle AgedAnalgesics OpioidAnesthesiology and Pain MedicineOpioidAnesthesiaNeuropathic painDisease ProgressionFemaleNeurology (clinical)medicine.symptombusinessCancer painmedicine.drug
researchProduct

Effects of age and gender in patients receiving doses of opioids for breakthrough pain proportional to background opioid doses.

2019

Aim: To identify the role of age and gender in analgesic and adverse effects after administering fentanyl products for breakthrough pain (BT), given in doses proportional to opioid doses given for background pain. Methods: Data from nine studies, in which patients with BP were given fentanyl products in doses proportional to their basal opioid regimen, were analyzed. Results: A total 462 patients presenting 1905 episodes of BP were included in this analysis. In older patients, the decrease in pain intensity was more pronounced 15 min after administration of a BP medication. No gender differences were found. No significant differences in frequency and intensity of adverse effects for age and…

MalePain medicineAnalgesicFentanyl03 medical and health sciencesBasal (phylogenetics)Age0302 clinical medicinemedicineHumans030212 general & internal medicineCancer painAdverse effectAgedPain Measurementbusiness.industryBreakthrough PainAge FactorsGenderGender IdentityFentanylAnalgesics OpioidRegimenTreatment OutcomeOncologyOpioid030220 oncology & carcinogenesisAnesthesiaFemaleCancer painbusinessmedicine.drugSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
researchProduct

The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting.

2013

Abstract The dose of rapid onset opioids to be given for breakthrough cancer pain (BTcP) is controversial. Dose proportional to the basal opioid regimen seem to be safe and effective in hospital units. However, data in other less protected settings, like home care, are lacking. The aim of this open-label study was to assess the efficacy and safety in a group of patients with BTcP followed at home, after giving a dose of fentanyl buccal tablets (FBT) proportional to the opioid basal regimen, skipping the steps for dose titration. Consecutive patients admitted to a home care program presenting BTcP episodes and receiving stable doses of opioids for background pain were selected. Data from fou…

MalePain medicineSettore MED/41 - AnestesiologiaOpioidSettore MED/42 - Igiene Generale E ApplicataHome careFentanylDose-Response RelationshipBuccalBreakthrough-episodic painNeoplasmsmedicine80 and overHumansCancer painAdverse effectAgedPain MeasurementAged 80 and overAnalgesicsDose-Response Relationship Drugbusiness.industryBreakthrough PainAdministration BuccalBuccal administrationMiddle AgedFentanyl buccal tabletHome Care ServicesAnalgesics OpioidOpioidsFentanylRegimenTreatment OutcomeBasal (medicine)OpioidOncologyCancer pain; Breakthrough-episodic pain; Fentanyl buccal tablet; Opioids; Home careAnesthesiaAdministrationFemaleBreakthrough-episodic pain; Cancer pain; Fentanyl buccal tablet; Home care; Opioids; Administration Buccal; Aged; Aged 80 and over; Analgesics Opioid; Breakthrough Pain; Dose-Response Relationship Drug; Female; Fentanyl; Home Care Services; Humans; Male; Middle Aged; Neoplasms; Pain Measurement; Tablets; Treatment Outcome; OncologyDrugCancer painbusinessmedicine.drugTablets
researchProduct

The use of sublingual fentanyl for breakthrough pain by using doses proportional to opioid basal regimen.

2013

Abstract OBJECTIVE: The aim of this study was to prospectively assess the efficacy and safety of sublingual fentanyl (SLF) in doses proportional to opioid doses used for background analgesia for the treatment of BTP of cancer patients. METHODS: A sample of patients admitted to an acute palliative care unit, presenting breakthrough pain (BTP) episodes and receiving stable doses of opioids for background pain was selected to assess the efficacy and safety of SLF used in doses proportional to the basal opioid regimen used for the management of BTP. For each patient, data from four consecutive episodes were collected. For each episode, nurses collected changes in pain intensity and adverse effe…

MalePalliative careAdministration SublingualSettore MED/41 - AnestesiologiaMANAGEMENT BTPSettore MED/42 - Igiene Generale E ApplicataFentanylQuality of lifemedicineHumansAdverse effectAgedPain Measurementbreakthrough pain; FENTANYL; MANAGEMENT BTPbusiness.industryPalliative CareFENTANYLGeneral MedicineMiddle Agedbreakthrough painAnalgesics OpioidRegimenTreatment OutcomeBasal (medicine)OpioidAnesthesiaQuality of LifeFemalebusinessCancer painmedicine.drug
researchProduct

Ineffectiveness of dextromethorphan in cancer pain

1998

Experimental studies have indicated that N-methyl-D-aspartate (NMDA) receptor antagonists may be effective analgesics in a wide variety of chronic pain states. The mechanism is presumed to be related to decreased firing of dorsal horn neurons after constant repeated C-fiber stimulation. Dextromethorphan (DM), a potent NMDA antagonist with a good safety profile, may be a promising agent for the treatment of persistent pain. An open-label randomized trial was designed to examine the effects of combining DM with NSAIDs, dextropropoxyphene, or morphine in cancer patients with pain. Patients who required a change in the step of the World Health Organization's (WHO) analgesic ladder because of a …

MalePalliative careAnalgesicNeuropathic painDextromethorphanNeoplasmsWHO methodmedicineHumansCancer painGeneral NursingNursing (all)2901 Nursing (miscellaneous)DextropropoxypheneMorphinebusiness.industryPalliative CareChronic painPain scaleMiddle Agedmedicine.diseasePain IntractableAnalgesics OpioidAnesthesiology and Pain MedicineOpioidAnesthesiaNeuropathic painDrug Therapy CombinationFemaleIntractable painNeurology (clinical)businessCancer painExcitatory Amino Acid Antagonistsmedicine.drug
researchProduct

The use of opioids for breakthrough pain in acute palliative care unit by using doses proportional to opioid basal regimen.

2010

OBJECTIVES: To determine the efficacy and safety of different opioids used in doses proportional to the basal opioid regimen for the management of breakthrough pain (BP). METHODS: In 66 patients consecutive patients admitted to a pain relief and palliative care unit, the efficacy and safety of different opioids used in doses proportional to the basal opioid regimen for the management of breakthrough pain (BP) were assessed. The choice of the opioid to be administered as rescue medication was based on the characteristics of patients, clinical stability, compliance, preference, and so on. For each episode, nurses were instructed to routinely collect changes in pain intensity and emerging prob…

MalePalliative careBreakthrough PainAdministration OralPainDrug Administration ScheduleSex FactorsClinical ProtocolsMedicinebreakthrough pain; acute palliative care unit; opioidsHumansAgedPain MeasurementAnalgesicsDose-Response Relationship Drugbusiness.industryPalliative CareAge FactorsopioidsMiddle Agedacute palliative care unitbreakthrough painClinical trialAnalgesics OpioidRegimenAnesthesiology and Pain MedicineNociceptionTreatment OutcomeBasal (medicine)OpioidAnesthesiaFemaleNeurology (clinical)businessCancer painmedicine.drug
researchProduct